Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Wave Life Sciences Ltd. WVE
$3.94
+$0.07 (1.68%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
383650426.00000000
-
week52high
7.12
-
week52low
1.16
-
Revenue
3649000
-
P/E TTM
-2
-
Beta
-0.90588200
-
EPS
-2.04000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 12:30
Описание компании
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Market Perform | Market Perform | 13 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 13 мая 2022 г. |
| SVB Leerink | Market Perform | 30 мар 2021 г. | |
| RBC Capital | Sector Perform | 23 окт 2020 г. | |
| H.C. Wainwright | Buy | Buy | 02 янв 2020 г. |
| RBC Capital | Sector Perform | Sector Perform | 11 ноя 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 14 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Verdine Gregory L. | A | 163467 | 163467 | 27 окт 2022 г. |
| Tan Aik Na | A | 21000 | 21000 | 15 авг 2022 г. |
| CORRIGAN MARK | A | 21000 | 21000 | 15 авг 2022 г. |
| TAKANASHI KEN | A | 21000 | 21000 | 15 авг 2022 г. |
| Wagner Heidi L | A | 21000 | 21000 | 15 авг 2022 г. |
| Verdine Gregory L. | A | 21000 | 21000 | 15 авг 2022 г. |
| HENRY CHRISTIAN O | A | 21000 | 21000 | 15 авг 2022 г. |
| Rawcliffe Adrian | A | 21000 | 21000 | 15 авг 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 21000 | 21000 | 15 авг 2022 г. |
| Moran Kyle | A | 60000 | 60000 | 25 июл 2022 г. |
Новостная лента
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
03 мая 2023 г. в 10:40
Wave Life Sciences (WVE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.62 per share a year ago.
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
GlobeNewsWire
29 мар 2023 г. в 08:00
CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Guggenheim Genomic Medicines and Rare Disease Days in New York City on Monday, April 3, 2023 at 2:10 p.m. ET.
Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
22 мар 2023 г. в 09:57
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.90% and 47.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
GlobeNewsWire
02 мар 2023 г. в 08:30
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 22, 2023, to discuss the company's fourth quarter and full year 2022 financial results and provide a business update.
Wave Life Sciences (WVE) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
14 февр 2023 г. в 13:33
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).